{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:40:18Z","timestamp":1781840418300,"version":"3.54.5"},"reference-count":99,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1191368"],"award-info":[{"award-number":["GNT1191368"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1194325"],"award-info":[{"award-number":["GNT1194325"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.05.092","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T22:35:37Z","timestamp":1623278137000},"page":"7238-7252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis"],"prefix":"10.1016","volume":"39","author":[{"given":"Stephen","family":"Muhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-123X","authenticated-orcid":false,"given":"Timothy P.","family":"Stinear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/path.1700600111","article-title":"A new mycobacterial infection in man","volume":"60","author":"MacCallum","year":"1948","journal-title":"J Pathology Bacteriol."},{"key":"10.1016\/j.vaccine.2021.05.092_b0010","first-page":"585","article-title":"Study of a mycobacterium causing skin ulceration in Uganda. Ann De La Soci\u00e9t\u00e9 Belge De","volume":"42","author":"Clancey","year":"1962","journal-title":"M\u00e9decine Tropicale."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3201\/eid2603.ET2603","article-title":"Etymologia: Buruli ulcer","volume":"26","author":"Henry","year":"2020","journal-title":"Emerg Infect Dis."},{"issue":"10066","key":"10.1016\/j.vaccine.2021.05.092_b0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(16)30171-4","article-title":"Neglected tropical diseases: progress towards addressing the chronic pandemic","volume":"389","author":"Molyneux","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.05.092_b0025","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/752749","article-title":"Buruli ulcer induced disability in Ghana: A study at Apromase in the Ashanti region","volume":"2012","author":"Agbenorku","year":"2012","journal-title":"Plastic Surg Int."},{"issue":"11","key":"10.1016\/j.vaccine.2021.05.092_b0030","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3201\/eid2411.171593","article-title":"Epidemiology of Buruli ulcer infections, Victoria, Australia, 2011\u20132016","volume":"24","author":"Loftus","year":"2018","journal-title":"Emerg Infect Dis."},{"issue":"7","key":"10.1016\/j.vaccine.2021.05.092_b0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5694\/mja17.00879","article-title":"Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response","volume":"208","author":"O\u2019Brien","year":"2018","journal-title":"Med J Australia."},{"issue":"10","key":"10.1016\/j.vaccine.2021.05.092_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002463","article-title":"The incubation period of Buruli ulcer (Mycobacterium ulcerans infection)","volume":"7","author":"Trubiano","year":"2013","journal-title":"Plos Neglect Trop D."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006323","article-title":"The incubation period of Buruli ulcer (Mycobacterium ulcerans infection) in Victoria, Australia \u2013 Remains similar despite changing geographic distribution of disease","volume":"12","author":"Loftus","year":"2018","journal-title":"Plos Neglect Trop D."},{"issue":"5706","key":"10.1016\/j.vaccine.2021.05.092_b0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/bmj.2.5706.390","article-title":"Clinical features and treatment of pre-ulcerative Buruli lesions (Mycobacterium ulcerans infection). Report II of the Uganda Buruli Group","volume":"2","author":"Bradley","year":"1970","journal-title":"Brit Med J."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/CVI.00235-08","article-title":"Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans","volume":"16","author":"Sarfo","year":"2009","journal-title":"Clin Vaccine Immunol."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007178","article-title":"Spontaneous healing of Mycobacterium ulcerans disease in Australian patients","volume":"13","author":"O\u2019Brien","year":"2019","journal-title":"Plos Neglect Trop D."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1445-2197.1969.tb06535.x","article-title":"The Bairnsdale ulcer","volume":"41","author":"Alsop","year":"1972","journal-title":"Aust Nz J Surg."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1445-5994.1975.tb03649.x","article-title":"Mycobacterium ulcerans in Australia","volume":"5","author":"Radford","year":"1975","journal-title":"Aust Nz J Med."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003503","article-title":"Mycobacterium ulcerans treatment \u2013 Can antibiotic duration be reduced in selected patients?","volume":"9","author":"Cowan","year":"2015","journal-title":"Plos Neglect Trop D."},{"issue":"10232","key":"10.1016\/j.vaccine.2021.05.092_b0080","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0140-6736(20)30047-7","article-title":"Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial","volume":"395","author":"Phillips","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.092_b0085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/imj.13511","article-title":"Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients","volume":"47","author":"O\u2019Brien","year":"2017","journal-title":"Intern Med J."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1101\/gr.5942807","article-title":"Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer","volume":"17","author":"Stinear","year":"2007","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0095","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2164-13-258","article-title":"On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer","volume":"13","author":"Doig","year":"2012","journal-title":"BMC Genomics"},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0100","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/IAI.71.2.922-929.2003","article-title":"Transposon mutagenesis of Mycobacterium marinum identifies a locus linking pigmentation and intracellular survival","volume":"71","author":"Gao","year":"2003","journal-title":"Infect Immun."},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.092_b0105","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1462-5822.2005.00557.x","article-title":"Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo","volume":"7","author":"Adusumilli","year":"2005","journal-title":"Cell Microbiol."},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.092_b0110","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1073\/pnas.0305877101","article-title":"Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans","volume":"101","author":"Stinear","year":"2004","journal-title":"P Natl Acad Sci Usa."},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.092_b0115","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1128\/JB.187.5.1668-1676.2005","article-title":"Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans","volume":"187","author":"Stinear","year":"2005","journal-title":"J Bacteriol."},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.092_b0120","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/JB.01442-06","article-title":"Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor","volume":"189","author":"Yip","year":"2007","journal-title":"J Bacteriol."},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.092_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000580","article-title":"Genomic diversity and evolution of Mycobacterium ulcerans revealed by next-generation sequencing","volume":"5","author":"Qi","year":"2009","journal-title":"Plos Pathog."},{"issue":"7","key":"10.1016\/j.vaccine.2021.05.092_b0130","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1128\/jcm.35.7.1696-1700.1997","article-title":"Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection","volume":"35","author":"Ross","year":"1997","journal-title":"J Clin Microbiol."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0135","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1128\/JCM.37.4.1018-1023.1999","article-title":"Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR","volume":"37","author":"Stinear","year":"1999","journal-title":"J Clin Microbiol."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2148-7-177","article-title":"Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans","volume":"7","author":"K\u00e4ser","year":"2007","journal-title":"Bmc Evol Biol."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1039\/b803101k","article-title":"Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria","volume":"25","author":"Hong","year":"2008","journal-title":"Nat Prod Rep."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nrmicro2077","article-title":"Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans","volume":"7","author":"Demangel","year":"2009","journal-title":"Nat Rev Microbiol."},{"issue":"10","key":"10.1016\/j.vaccine.2021.05.092_b0155","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1128\/IAI.73.10.6299-6310.2005","article-title":"Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice","volume":"73","author":"Oliveira","year":"2005","journal-title":"Infect Immun."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0160","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/IAI.68.2.877-883.2000","article-title":"A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells","volume":"68","author":"George","year":"2000","journal-title":"Infect Immun."},{"issue":"7","key":"10.1016\/j.vaccine.2021.05.092_b0165","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1242\/jcs.182352","article-title":"Mechanistic insights into the inhibition of Sec61-dependent co- and post-translational translocation by mycolactone","volume":"129","author":"McKenna","year":"2016","journal-title":"J Cell Sci."},{"issue":"13","key":"10.1016\/j.vaccine.2021.05.092_b0170","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1084\/jem.20160662","article-title":"Mycolactone subverts immunity by selectively blocking the Sec61 translocon","volume":"213","author":"Baron","year":"2016","journal-title":"J Exp Medicine."},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.092_b0175","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1021\/acschembio.7b00053","article-title":"The macrolide toxin mycolactone promotes Bim-dependent apoptosis in Buruli ulcer through inhibition of mTOR","volume":"12","author":"Bieri","year":"2017","journal-title":"Acs Chem Biol."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0180","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41419-018-0427-y","article-title":"Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4","volume":"9","author":"Ogbechi","year":"2018","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0185","article-title":"Mycobacterium ulcerans infection (with comments on pathogenesis)","volume":"33","author":"Connor","year":"1965","journal-title":"Int J Leprosy."},{"issue":"8","key":"10.1016\/j.vaccine.2021.05.092_b0190","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1080\/21505594.2017.1370530","article-title":"Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria","volume":"8","author":"Ruf","year":"2017","journal-title":"Virulence."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0195","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/IAI.00889-06","article-title":"Evidence for an intramacrophage growth phase of Mycobacterium ulcerans","volume":"75","author":"Torrado","year":"2007","journal-title":"Infect Immun."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004061","article-title":"The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER","volume":"10","author":"Hall","year":"2014","journal-title":"Plos Pathog."},{"issue":"163","key":"10.1016\/j.vaccine.2021.05.092_b0205","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.4049\/jimmunol.163.7.3928","article-title":"The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte\/T cell cytokine production and NF-\u03baB function","volume":"7","author":"Pahlevan","year":"1999","journal-title":"J Immunol."},{"issue":"11","key":"10.1016\/j.vaccine.2021.05.092_b0210","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1086\/646615","article-title":"Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with Buruli ulcer disease","volume":"200","author":"Phillips","year":"2009","journal-title":"J Infect Dis."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0215","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/IAI.69.3.1704-1707.2001","article-title":"Immune response to infection with Mycobacterium ulcerans","volume":"69","author":"Gooding","year":"2001","journal-title":"Infect Immun."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0220","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4049\/jimmunol.0902717","article-title":"IFN-\u03b3\u2013dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone","volume":"184","author":"Torrado","year":"2010","journal-title":"J Immunol."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004450","article-title":"Interferon-\u03b3 Is a crucial activator of early host immune defense against Mycobacterium ulcerans infection in mice","volume":"10","author":"Bieri","year":"2016","journal-title":"Plos Neglect Trop D."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0230","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1128\/AAC.05543-11","article-title":"Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model","volume":"56","author":"Ruf","year":"2012","journal-title":"Antimicrob Agents Ch."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(06)70412-1","article-title":"The role of BCG in prevention of leprosy: a meta-analysis","volume":"6","author":"Setia","year":"2006","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.092_b0240","doi-asserted-by":"crossref","unstructured":"Group KPT. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 1996;348(9019):17\u201324.","DOI":"10.1016\/S0140-6736(96)02166-6"},{"issue":"10","key":"10.1016\/j.vaccine.2021.05.092_b0245","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol."},{"issue":"7650","key":"10.1016\/j.vaccine.2021.05.092_b0250","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7586","key":"10.1016\/j.vaccine.2021.05.092_b0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(69)91133-7","article-title":"BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer): First results of a trial in Uganda","volume":"293","author":"Uganda Buruli Group","year":"1969","journal-title":"Lancet"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2021.05.092_b0260","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0035-9203(76)90128-0","article-title":"The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda","volume":"70","author":"Smith","year":"1976","journal-title":"T Roy Soc Trop Med H."},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.092_b0265","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/0035-9203(93)90272-R","article-title":"Epidemiology of Buruli ulcer in Amansie West district, Ghana","volume":"87","author":"Amofah","year":"1993","journal-title":"T Roy Soc Trop Med H."},{"issue":"10","key":"10.1016\/j.vaccine.2021.05.092_b0270","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/429623","article-title":"Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection): Results from a case-control study in Ghana","volume":"40","author":"Raghunathan","year":"2005","journal-title":"Clin Infect Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003457","article-title":"Effectiveness of routine BCG vaccination on Buruli ulcer disease: A case-control study in the Democratic Republic of Congo, Ghana and Togo","volume":"9","author":"Phillips","year":"2015","journal-title":"Plos Neglect Trop D."},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.092_b0280","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3201\/eid1209.050598","article-title":"Risk factors for Buruli ulcer","volume":"12","author":"Debacker","year":"2006","journal-title":"Benin. Emerg Infect Dis."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0285","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4269\/ajtmh.2006.75.768","article-title":"BCG vaccine effectiveness against Buruli ulcer: A case-control study in Benin","volume":"75","author":"Nackers","year":"2006","journal-title":"Am J Tropical Medicine Hyg."},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.092_b0290","first-page":"1389","article-title":"Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli ulcer)","volume":"9","author":"Portaels","year":"2002","journal-title":"Clin Diagn Lab Immun."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0295","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.72.1.62-65.2004","article-title":"Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease","volume":"72","author":"Portaels","year":"2004","journal-title":"Infect Immun."},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.092_b0300","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4269\/ajtmh.2004.70.520","article-title":"Buruli ulcer disease in Cameroon rediscovered","volume":"70","author":"Noeske","year":"2004","journal-title":"Am J Tropical Medicine Hyg."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0305","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.vaccine.2008.10.058","article-title":"Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis","volume":"27","author":"Horwitz","year":"2009","journal-title":"Vaccine."},{"issue":"12","key":"10.1016\/j.vaccine.2021.05.092_b0310","first-page":"1133","article-title":"BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size","volume":"4","author":"Floyd","year":"2000","journal-title":"Int J Tuberc Lung Dis Official J Int Union Against Tuberc Lung Dis."},{"issue":"8","key":"10.1016\/j.vaccine.2021.05.092_b0315","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.micinf.2006.03.009","article-title":"Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer","volume":"8","author":"Coutanceau","year":"2006","journal-title":"Microbes Infect."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0320","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00753-19","article-title":"Vaccine-specific immune responses against Mycobacterium ulcerans infection in a low-dose murine challenge model","volume":"88","author":"Mangas","year":"2019","journal-title":"Infect Immun."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0325","first-page":"76","article-title":"Homologous and heterologous immunity in infections of mice with Mycobacterium ulcerans and Mycobacterium balnei","volume":"76","author":"Fenner","year":"1957","journal-title":"Am Rev Tuberc Pulm."},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.092_b0330","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1128\/IAI.01622-06","article-title":"A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice","volume":"75","author":"Tanghe","year":"2007","journal-title":"Infect Immun."},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.092_b0335","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"Innate immune response in Th1-and Th2-dominant mouse strains","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000985","article-title":"BCG-mediated protection against Mycobacterium ulcerans infection in the mouse","volume":"5","author":"Converse","year":"2011","journal-title":"Plos Neglect Trop D."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0345","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.chom.2019.03.009","article-title":"The Collaborative Cross: A systems genetics resource for studying host-pathogen interactions","volume":"25","author":"Noll","year":"2019","journal-title":"Cell Host Microbe."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0350","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/IAI.74.1.202-212.2006","article-title":"Members of the 30- to 32-kiloDalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle","volume":"74","author":"Rosseels","year":"2006","journal-title":"Infect Immun."},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.092_b0355","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1128\/IAI.69.9.5403-5411.2001","article-title":"Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer","volume":"69","author":"Tanghe","year":"2001","journal-title":"Infect Immun."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000199","article-title":"Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting","volume":"2","author":"Tanghe","year":"2008","journal-title":"Plos Neglect Trop D."},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.092_b0365","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","article-title":"BCG-induced trained immunity: can it offer protection against COVID-19?","volume":"20","author":"O\u2019Neill","year":"2020","journal-title":"Nat Rev Immunol."},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.092_b0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004046","article-title":"Recombinant BCG expressing Mycobacterium ulcerans Ag85A imparts enhanced protection against experimental Buruli ulcer","volume":"9","author":"Hart","year":"2015","journal-title":"Plos Neglect Trop D."},{"key":"10.1016\/j.vaccine.2021.05.092_b0375","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.trivac.2016.04.001","article-title":"Immunogenicity and protection conferred by a recombinant Mycobacterium marinum vaccine against Buruli ulcer","volume":"5","author":"Hart","year":"2016","journal-title":"Trials Vaccinol."},{"issue":"12","key":"10.1016\/j.vaccine.2021.05.092_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005229","article-title":"Overexpression of a Mycobacterium ulcerans Ag85B-EsxH fusion protein in recombinant BCG improves experimental Buruli ulcer vaccine efficacy","volume":"10","author":"Hart","year":"2016","journal-title":"Plos Neglect Trop D."},{"issue":"10","key":"10.1016\/j.vaccine.2021.05.092_b0385","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.molmed.2012.07.008","article-title":"Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions","volume":"18","author":"Gowthaman","year":"2012","journal-title":"Trends Mol Med."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0390","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vaccine.2006.07.020","article-title":"The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children","volume":"25","author":"Hesseling","year":"2007","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.092_b0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033406","article-title":"Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination","volume":"7","author":"Fraga","year":"2012","journal-title":"PLoS ONE"},{"issue":"19","key":"10.1016\/j.vaccine.2021.05.092_b0400","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.vaccine.2015.03.046","article-title":"Protective effect of a dewaxed whole-cell vaccine against Mycobacterium ulcerans infection in mice","volume":"33","author":"Watanabe","year":"2015","journal-title":"Vaccine."},{"issue":"8","key":"10.1016\/j.vaccine.2021.05.092_b0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004011","article-title":"Use of recombinant virus replicon particles for vaccination against Mycobacterium ulcerans disease","volume":"9","author":"Bolz","year":"2015","journal-title":"Plos Neglect Trop D."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004431","article-title":"Vaccination with the surface proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans induces antibodies but fails to provide protection against Buruli ulcer","volume":"10","author":"Bolz","year":"2016","journal-title":"Plos Neglect Trop D."},{"key":"10.1016\/j.vaccine.2021.05.092_b0415","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9659","article-title":"High antibody titres induced by protein subunit vaccines using Mycobacterium ulcerans antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice","volume":"8","author":"Mangas","year":"2020","journal-title":"PeerJ"},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003477","article-title":"Identification of the Mycobacterium ulcerans protein MUL_3720 as a promising target for the development of a diagnostic test for Buruli ulcer","volume":"9","author":"Dreyer","year":"2015","journal-title":"Plos Neglect Trop D."},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.092_b0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004808","article-title":"Antibody-mediated neutralization of the exotoxin mycolactone, the main virulence factor produced by Mycobacterium ulcerans","volume":"10","author":"Dangy","year":"2016","journal-title":"Plos Neglect Trop D."},{"issue":"7","key":"10.1016\/j.vaccine.2021.05.092_b0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070520","article-title":"The cell wall-associated mycolactone polyketide synthases are necessary but not sufficient for mycolactone biosynthesis","volume":"8","author":"Porter","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002604","article-title":"Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice","volume":"8","author":"Roupie","year":"2014","journal-title":"Plos Neglect Trop D."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005553","article-title":"Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer","volume":"11","author":"Wallace","year":"2017","journal-title":"Plos Neglect Trop D."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.092_b0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002668","article-title":"Potential wildlife sentinels for monitoring the endemic spread of human Buruli ulcer in south-east Australia","volume":"8","author":"Carson","year":"2014","journal-title":"Plos Neglect Trop D."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0450","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.vaccine.2020.10.075","article-title":"Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group","volume":"39","author":"Jamrozik","year":"2020","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.05.092_b0455","article-title":"Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.092_b0460","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fmed.2018.00297","article-title":"Controlled human infections as a tool to reduce uncertainty in clinical vaccine development","volume":"5","author":"Roestenberg","year":"2018","journal-title":"Frontiers Medicine."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0465","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1586\/14760584.2.4.561","article-title":"Prospects for vaccine development against Buruli disease","volume":"2","author":"Huygen","year":"2003","journal-title":"Expert Rev Vaccines."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.092_b0470","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00430-009-0109-6","article-title":"Buruli ulcer disease: prospects for a vaccine","volume":"198","author":"Huygen","year":"2009","journal-title":"Med Microbiol Immun."},{"issue":"11","key":"10.1016\/j.vaccine.2021.05.092_b0475","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.4161\/hv.7.11.17751","article-title":"Buruli ulcer","volume":"7","author":"Einarsdottir","year":"2011","journal-title":"Hum Vaccines."},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.092_b0480","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/infdis\/jiy207","article-title":"Does BCG vaccination protect against nontuberculous mycobacterial Infection? A systematic review and meta-analysis","volume":"218","author":"Zimmermann","year":"2018","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.092_b0485","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3389\/fmicb.2020.01018","article-title":"Buruli ulcer: The efficacy of innate immune defense may be a key determinant for the outcome of infection with Mycobacterium ulcerans","volume":"11","author":"R\u00f6ltgen","year":"2020","journal-title":"Front Microbiol."},{"key":"10.1016\/j.vaccine.2021.05.092_b0490","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.molimm.2020.02.009","article-title":"Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans\u2014An integrated vaccinomics approach","volume":"120","author":"Nain","year":"2020","journal-title":"Mol Immunol."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.092_b0495","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4269\/ajtmh.2004.71.387","article-title":"Assessing water-related risk factors for Buruli ulcer: a case-control study in Ghana","volume":"71","author":"Aiga","year":"2004","journal-title":"Am J Tropical Medicine Hyg."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21007003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21007003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:44Z","timestamp":1759403204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21007003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":99,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21007003"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.092","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}